Further, it has been known since recently that m-CRC with mutated RAS is resistant to anti-EGFR therapies (64, 65), and those with MSI phenotype are sensitive to immunotherapy (66, 67), but colorectal cancer with BRAF mutation/s is awaiting such a specific chemotherapeutic approach. This evidence concerns the gene BRAF and colorectal cancer.